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Abstract: In this review, we discuss the pharmacological and clinical properties of irbesartan, 
a noncompetitive angiotensin II receptor type 1 antagonist, successfully used for more than a 
decade in the treatment of essential hypertension. Irbesartan exerts its antihypertensive effect 
through an inhibitory effect on the pressure response to angiotensin II. Irbesartan 150–300 mg 
once daily confers a lasting effect over 24 hours, and its antihypertensive efficacy is further 
enhanced by the coadministration of hydrochlorothiazide. Additionally and partially beyond its 
blood pressure-lowering effect, irbesartan reduces left ventricular hypertrophy, favors right atrial 
remodeling in atrial fibrillation, and increases the likelihood of maintenance of sinus rhythm 
after cardioversion in atrial fibrillation. In addition, the renoprotective effects of irbesartan are 
well documented in the early and later stages of renal disease in type 2 diabetics. Furthermore, 
both the therapeutic effectiveness and the placebo-like side effect profile contribute to a high 
adherence rate to the drug. Currently, irbesartan in monotherapy or combination therapy with 
hydrochlorothiazide represent a rationale pharmacologic approach for arterial hypertension and 
early-stage and late-stage diabetic nephropathy in hypertensive type II diabetics.
Keywords: AT1 receptor blockers, renin-angiotensin-aldosterone system, heart, renal, arterial, 
hypertension
Introduction
The renin-angiotensin-aldosterone system plays a pivotal role in the regulation of blood 
pressure and body sodium and water homeostasis. The renin-angiotensin-aldosterone 
system is implicated in the pathogenesis and progression of numerous cardiovascular 
and renal pathologies, including hypertension, structural cardiac remodeling, myo-
cardial infarction, heart failure, and chronic kidney disease.1,2 The inhibition of the 
renin-angiotensin-aldosterone system is therefore a therapeutic target.
In our pharmacological arsenal, we currently have four weapons that inhibit the renin-
angiotensin-aldosterone system through either direct or complementary  mechanisms. 
Angiotensin-converting enzyme inhibitors block the conversion of angiotensin I to 
angiotensin II; angiotensin receptor blockers selectively antagonize angiotensin II at 
the AT1 receptors; aldosterone receptor blockers reduce the effects of aldosterone; and 
renin inhibitors, the newest drug group, directly inhibit human renin.
Angiotensin receptor blockers have been available for management of hyper-
tension for almost 20 years. So far, seven angiotensin receptor blockers have been 
approved by the US Food and Drug Administration, with slightly different therapeutic 
indications (Table 1). In comparison with angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers have very similar antihypertensive efficacy, but a better 
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side effect profile, mainly because they are not associated 
with cough, a major side effect of ACE inhibitors.3,4 Several 
angiotensin receptor blockers have a long plasma half-life 
and binding time to the AT1 receptor, enabling a once a day 
administration. Because the side effect profile of drugs and 
the complexity of dosage regimens are known to have the 
greatest impact on patient adherence, angiotensin receptor 
blockers have an ideal profile, with a placebo-like tolerability 
and pharmacokinetic properties allowing a once-daily dos-
ing regimen.5
Irbesartan (Aprovel®, Avapro®, Irbetan®, Karvea®) is 
a well established angiotensin receptor blocker, approved 
worldwide for the treatment of hypertension. In essential 
hypertension, irbesartan lowers blood pressure over 24 hours. 
The usual starting dosage is 150 mg once daily, but the dose 
can be uptitrated to 300 mg once daily if necessary.6 In many 
countries (US, Canada, Europe), irbesartan is also approved 
for the treatment of nephropathy in patients with hypertension 
and type 2 diabetes mellitus. In the latter indication, 300 mg 
once daily is the recommended maintenance dosage.6
This review summarizes the pharmacokinetic and phar-
macodynamic characteristics of irbesartan, with a particular 
focus on recent clinical evidence about the therapeutic effi-
cacy and tolerability of irbesartan when used as oral mono-
therapy or combination therapy in essential hypertension, 
diabetic nephropathy, and cardiac disease.
Overview of pharmacology
Irbesartan is an imidazole derivative with a bipentyl-tetrazole 
side chain. It does not require biotransformation to exert its 
pharmacological action. The molecule has a high affinity 
for the AT1 receptor in human vascular smooth muscle 
cells, inducing in vitro a rightward shift of the angiotensin II 
 concentration-response curve and a depression of the maximal 
response to angiotensin II characteristic of insurmountable 
blockade of AT1 receptors.7 Following oral administration, 
Table 1 Indications of the seven approved angiotensin receptor blocker (listed in order of date of appearance on the market)89,90
Essential 
hypertension
Heart failure Cardiovascular 
prevention
Nephropathy
Losartan X X 
Symptomatic 
NYHA II–IIIa
X 
↓ stroke risk in LvH
X 
Hypertensive, 
type II diabetics
(↑ creatinine 
and/or albuminuria 
$300 mg/day)
Valsartan X X 
Symptomatic 
NYHA II–IIIb
X 
Asymptomatic 
if recent MI 
and LveF # 40%
Candesartan X X 
If LveF # 40%a
Irbesartan X X 
Hypertensive, type II 
diabetics, (↑ creatinine 
and/or albuminuria 
$30 mg/day)
Olmesartan X
Telmisartan X X 
↓ MI and stroke risk 
in high Cv risk 
and/or diabetic 
patients with target 
organ damage
Eprosartan X
Notes: aAs add-on therapy to angiotensin-converting enzyme inhibitors or as an alternative to angiotensin-converting enzyme inhibitors in patients unable to tolerate 
angiotensin-converting enzyme inhibitors; bAs add-on therapy to angiotensin-converting enzyme inhibitors when beta-blockers cannot be used or as an alternative to 
angiotensin-converting enzyme inhibitors in patients unable to tolerate angiotensin-converting enzyme inhibitors; ↓ indicates decrease. 
Abbreviations: ARB, angiotensin receptor blocker; ACe-I, ACe inhibitor; LveF, left ventricular ejection fraction; Cv, cardiovascular; MI, myocardial infarction; LvH, left 
ventricular hypertrophy.
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the absolute average bioavailability is high (60%–80%), 
the highest in its class, and is not affected by concomitant 
food intake.8 In healthy subjects, peak plasma concentration 
and the area under the curve are dose-dependent, whereas 
the time to peak plasma concentration is dose-independent 
(1.5–2.0 hours). Steady-state plasma concentrations are 
reached after three days of once-daily administration, with 
an elimination half-life of about 11–15 hours, and no evi-
dence of accumulation over one-week multiple dosing.9 The 
degree of plasma protein binding is $90%.10 Irbesartan is 
strongly metabolized via hepatic glucuronidation and oxida-
tion (mainly by the cytochrome P450 2C9 isoenzyme) and 
excreted by both biliary (80%) and renal (20%) routes. No 
active metabolites have been identified. No gender-related 
or age-related dosage adjustment is necessary, not even for 
patients with mild-to-moderate hepatic insufficiency, heart 
failure, or renal insufficiency.11–14 Irbesartan is strictly con-
traindicated in the second and third trimesters of pregnancy 
and during lactation.15
Drug interactions
Potential drug interactions with cytochrome P450 2C9 have 
been extensively analyzed.16 Fluconazole, a cytochrome P450 
2C9 inhibitor, increases steady-state peak plasma concentra-
tion (19%) and area under the curve (63%), without altering 
the time to peak plasma concentration.17 No data are available 
regarding the impact of this interaction on antihypertensive 
efficacy. The pharmacokinetic profile of irbesartan is not 
affected by nifedipine, warfarin, simvastatin, tolbutamide, 
hydrochlorothiazide, or magnesium-aluminum hydroxide 
antacids. Irbesartan does not alter the steady-state phar-
macokinetics of digoxin.6,16 When combined with a cyclo-
oxygenase 2 inhibitor in slightly volume-depleted subjects 
with normal renal function, irbesartan does not affect renal 
hemodynamics and renal salt handling.18 A pharmacogenetic 
study has confirmed the role of the cytochrome P450 2C9 
enzyme in the metabolism of irbesartan. In a Chinese popula-
tion, carriers of the cytochrome P450 2C9*3 allele had higher 
levels of irbesartan at 6 and 14 hours.19
Therapeutic efficacy  
in hypertension
The antihypertensive efficacy of irbesartan has been estab-
lished in numerous, large, randomized active-controlled or 
placebo-controlled trials of up to three months’ duration.20–34 
As expected, irbesartan in monotherapy is superior to placebo 
in lowering both systolic and diastolic blood pressure.15,30,31 
The blood pressure effect was manifest within two weeks of 
starting treatment, and achieved maximum reduction after 
2–6 weeks.30 A dose-response relationship over a dose range 
of 1–900 mg once daily was observed, reaching a plateau 
with doses $300 mg once daily.31 The placebo-subtracted 
reduction in office blood pressure was approximately 
8–10/5–6 mmHg.31 In studies involving ambulatory blood 
pressure assessment, irbesartan was effective in producing 
sustained 24-hour blood pressure control.22,23,29,35 A trough-
to-peak ratio $0.6 was achieved with doses $150 mg 
once daily.31
Comparative clinical trials performed in mild-to-moder-
ate hypertension showed equal efficacy, but better tolerability, 
compared with the other major antihypertensive classes, 
ie, beta-blockers (atenolol), calcium antagonists (amlo-
dipine), angiotensin-converting enzyme inhibitors (enalapril), 
and renin inhibitors (aliskiren), and superior efficacy as com-
pared with doxazosin.20–22,26–28,36–38 In intraclass comparative 
clinical trials (Table 2), irbesartan was at least as effective 
as losartan, significantly more effective than valsartan, but 
less effective than olmesartan at reducing office diastolic 
blood pressure.24,25,35,39 However, in an additional analysis 
considering 24-hour ambulatory blood pressure values as 
a secondary variable, no significant difference was found 
between olmesartan and irbesartan in terms of blood pres-
sure (13/9 mmHg for olmesartan 20 mg once daily versus 
11/7 mmHg for irbesartan 150 mg once daily (not statisti-
cally significant), nor in terms of the percentage of patients 
reaching a mean 24-hour blood pressure ,130/80 mmHg 
(21% versus 14%, not statistically significant).40
In a recent comparative study, we demonstrated significant 
differences between angiotensin receptor blockers in their 
capacity to induce sustained vascular blockade of angiotensin 
II receptors when the renin-angiotensin-aldosterone system is 
activated by a thiazide diuretic.41 The blood pressure response 
to angiotensin II infusion was reduced by more than 90% with 
irbesartan 300 mg, irbesartan- hydrochlorothiazide 300/25 mg, 
and/or olmesartan-hydrochlorothiazide 20/25 mg, and by 
nearly 60% with valsartan-hydrochlorothiazide 160/25 mg 
and losartan-hydrochlorothiazide 100/25 mg (P , 0.05). In the 
kidney, angiotensin II infusion reduced renal plasma flow by 
36% at baseline (P , 0.001). Irbesartan ±  hydrochlorothiazide 
and olmesartan-hydrochlorothiazide blocked the renal 
hemodynamic response to angiotensin II almost completely, 
whereas valsartan-hydrochlorothiazide and losartan-
 hydrochlorothiazide only blunted this effect, by 34% and 
45%, respectively.
Finally, a Portuguese group evaluated the effect of irbesar-
tan on the circadian rhythm of blood pressure. In  salt-sensitive 
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hypertensive patients with a nondipper profile on a high-salt 
diet (n = 12), irbesartan restored the nocturnal blood pressure 
decline in a dose-dependent manner.42
Efficacy in hypertension when 
combined with other drugs
Combination of an angiotensin receptor blocker with hydro-
chlorothiazide provides additive blood pressure reduction. 
There is a strong pathophysiological rationale supporting this 
association. Diuretic-induced reduction in total body sodium 
provokes a secondary rise of renin, which may counterbal-
ance its diuretic and antihypertensive effect. Simultaneously 
blocking the renin-angiotensin-aldosterone system prevents the 
action of a reactive hyperreninemia and maintains the blood 
pressure-lowering effect of salt depletion. The synergy between 
the two drugs has been shown in several clinical trials.
In a 4 × 4 placebo-controlled study involving 683 patients 
with mild-to-moderate hypertension, patients were random-
ized to one of 16 different double-blind combinations of 
irbesartan (0–300 mg once daily) and hydrochlorothiazide 
(0–25 mg once daily).34 At week 8, mean changes from 
baseline in trough blood pressure and total responder rates 
increased in a dose-dependent manner in both the single 
therapy and combination therapy groups. Combination 
therapy was more effective than either drug alone.
Two placebo-controlled studies performed in patients 
with mild-to-moderate hypertension showed that irbesartan 
75 mg or 150 mg + hydrochlorothiazide 12.5 mg reduced 
blood pressure more effectively than placebo or either drug 
alone in both seated trough blood pressure and 24-hour 
ambulatory blood pressure.32,43 Irbesartan 150 mg + hydro-
chlorothiazide 12.5 mg once daily resulted in reductions 
of 4–7/2–4 mmHg, additional to those with the individual 
 components.15 Further, the combination therapy reduced 
blood pressure in patients inadequately controlled by mono-
therapy with irbesartan or hydrochlorothiazide.33,44
The largest trial demonstrating the efficacy of irbesartan-
hydrochlorothiazide combination therapy was INCLUSIVE 
(Irbesartan-Hydrochlorothiazide Blood Pressure Reductions 
in Diverse Patient Populations), a prospective, open-label, 
single-arm study (n = 844). INCLUSIVE extended the previ-
ous reported findings by evaluating the efficacy and safety of a 
fixed combination in patients with uncontrolled systolic blood 
pressure after four weeks’ monotherapy. Progressive uptitra-
tion to high-dose irbesartan-hydrochlorothiazide 300/25 mg 
once daily, if necessary, lead to substantial reductions in 
systolic blood pressure (−23.0 ± 13.3 mmHg, P , 0.001) 
between baseline and week 18, and allowed systolic blood 
pressure goals to be attained in 75% of patients.
Endothelial effects
Angiotensin II has emerged as a key mediator of arterioscle-
rosis, by various pathogenic pathways. It induces vasocon-
striction, triggers oxidative stress, stimulates the release of 
Table 2 Antihypertensive efficacy of irbesartan, comparing oral irbesartan monotherapy with other classes of antihypertensive drugs 
in patients with mild-to-moderate hypertension
Comparison class (agent) Dosage (mg/day) IRB noninferior IRB superior IRB inferior
ACE inhibitor
eNA IRB 150–300, eNA 10–20 Chiou et al27
IRB 150–300, eNA 10–20 Coca et al22
IRB 150–300, eNA 10–20 Lacourciere20
IRB 75–300, eNA 5–10 Mimran et al21
Renin inhibitor
ALI IRB 150, ALI 150 Gradman et al36
IRB 150, ALI 300 Gradman et al36
Calcium channel blocker
AML IRB 150, AML 5 Gaudio et al61
Beta-blocker
ATe IRB 75–150, ATe 50–100 Stumpe et al28
Alpha-1 antagonist
DOX IRB 300, DOX 4 Derosa et al38
Angiotensin II receptor blockers
LOS IRB 150, LOS 100 Kassler-Taub et al24
IRB 300, LOS 100 Kassler-Taub et al24
IRB 200, LOS 100 Yoshinaga91
IRB 150–300, LOS 50–100 Oparil et al25
vAL IRB 150, vAL 80 Mancia et al23
OLM IRB 150, OLM 20 Oparil et al39
Abbreviations: ACe, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; BB, beta blocker; ATe, atenolol; IRB, irbesartan; eNA, enalapril; ALI, aliskiren; 
AML, amlodipine; LOS, losartan; OLM, olmesartan; vAL, valsartan; DOX, doxazosin.
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proinflammatory cytokines and growth factors, and induces 
a procoagulant state through activation of platelets and of the 
plasminogen-activator inhibitor. These pathophysiological 
effects are mediated by the AT1 receptor, whereas the AT2 
receptor might have protective functions.45 The vascular 
protective properties of irbesartan on vascular endothelium, 
proven in a number of in vitro and in vivo studies, have 
recently been reviewed in detail by Derosa.46,47
Efficacy in diabetic nephropathy
The efficacy of irbesartan at slowing the progression of renal 
damage in hypertensive type 2 diabetic patients was clearly 
demonstrated in PRIME (Program for Irbesartan Mortality 
and Morbidity Evaluation).48 PRIME consisted of two large 
(n .  500), at least two years in duration, randomized, double-
blind, placebo-controlled trials, ie, IRMA 2 (the Irbesartan 
Microalbuminuria Type 2 Diabetes on Hypertensive Patients 
trial)49 and IDNT (the Irbesartan in Diabetic Nephropathy 
trial).50
The IRMA 2 trial was performed in patients (n = 590) with 
early-stage renal damage, as indicated by microalbuminuria 
(30–300 mg/day) but normal creatinine levels.49 The aim of 
the study was to compare the effects of irbesartan 150 and 
300 mg once daily and placebo on the progression to overt 
nephropathy, defined as the conversion of microalbuminuria 
to albuminuria. In the two years of follow-up, the primary 
endpoint of overt nephropathy was reached by significantly 
fewer recipients of irbesartan 300 mg once daily compared 
with placebo (unadjusted hazards ratio for diabetic nephropa-
thy 0.3, 95% confidence interval [CI] 0.14–0.61, P , 0.001). 
Irbesartan 150 mg once daily significantly reduced urinary 
protein (albumin excretion rate) compared with placebo, 
but without attaining the primary endpoint. The effect of 
irbesartan on microalbuminuria was partly independent of 
its blood pressure-lowering effect.
IDNT evaluated the efficacy of irbesartan in 1715 hyper-
tensive, type 2 diabetic patients with established nephropathy, 
as indicated by overt proteinuria (.900 mg/day) and elevated 
serum creatinine.50 The relative risk of reaching the composite 
primary endpoint (doubling baseline serum creatinine level, 
onset of end-stage renal disease, or death from any cause) 
was significantly lower with irbesartan 300 mg once daily 
than with placebo (unadjusted relative risk 0.80, 95% CI 
0.66–0.97; P = 0.02) or with amlodipine 10 mg once daily 
(unadjusted relative risk 0.77, 95% CI 0.63–0.93; P = 0.006). 
Again, the difference remained significant after adjustment 
for mean arterial pressure, suggesting a blood pressure-
independent effect.
In a post hoc analysis of IDNT, the systolic blood 
pressure achieved strongly predicted renal outcome, and 
progressive lowering to 120 mmHg was associated with 
improved renal and patient survival, independently of 
baseline renal  function.51 Below this threshold, all-cause 
mortality increased. Additional evidence of a beneficial 
antiproteinuric effect of irbesartan beyond blood pressure 
control emerged from a small placebo-controlled crossover 
trial, where irbesartan improved microalbuminuria also in a 
normotensive subgroup of diabetic patients with early-stage 
microalbuminuric nephropathy.52
There are some arguments to explain this renoprotective 
effect. Irbesartan has been found to induce renal vasodilata-
tion without altering glomerular filtration rate, to improve 
endothelial function, and to reduce oxidative stress and 
inflammation in the kidney.49,53–58 In an animal model, 
irbesartan normalized the deficiency in podocytary nephrin 
expression, a protein involved in glomerular filtration bar-
rier function.59 All these data suggest that blockade of the 
AT1 receptor confers renal protection beyond its purely 
hemodynamic effect.
The recently published IMPROVE (Irbesartan in the 
Management of Proteinuric Patients at High Risk for Vas-
cular Events) study analyzed the potential benefit of a dual 
blockade of the renin-angiotensin-aldosterone system on 
albuminuria, in a population of hypertensive, mainly dia-
betic (87% with type 2 diabetes, 2% with type 1 diabetes 
patients at high cardiovascular risk, with albuminuric kidney 
disease.60 Patients were randomized to 20 weeks’ treatment 
with ramipril 10 mg + irbesartan 150–300 mg (both once 
daily) or ramipril 10 mg + placebo. The study showed no 
further benefit on albuminuria reduction in patients treated 
with combination therapy, despite better blood pressure 
control. Subgroup analyses showed that the largest reduction 
in albuminuria occurred in patients with overt nephropathy, 
without reaching statistical significance.
Efficacy in cardiac disease
The evidence of a positive impact of irbesartan on left ven-
tricular mass in patients with mild-to-moderate hyperten-
sion is based on two comparative trials, ie, an open-label/
blinded-endpoint study (n = 60) and a randomized double-
blind study (n = 115).61,62 Over a six-month period, irbesartan 
150–300 mg once daily was found to induce significantly 
greater left ventricular mass index regression than amlo-
dipine 5–10 mg once daily and atenolol 50–100 mg once 
daily, despite similar blood pressure control.61,62 Moreover, 
compared with atenolol, irbesartan significantly reduced QT 
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and corrected QT interval dispersion (the difference between 
maximal and minimal QT intervals within a 12-lead surface 
electrocardiogram), with a theoretical reduction in the risk of 
arrhythmias.63 There was a similar improvement of diastolic 
function in both groups, related to changes in ventricular 
geometry and blood pressure control for irbesartan, and only 
to blood pressure reduction for atenolol.64 Of note, similar 
beneficial cardiac effects have been demonstrated with other 
angiotensin receptor blockers, indicating that these effects 
are not unique to irbesartan.
In the IDNT trial, irbesartan reduced the incidence of 
congestive heart failure episodes (most, but not all, requiring 
hospitalization) compared with placebo (hazards ratio 0.72, 
95% CI 0.52–1.0; P = 0.048) or amlodipine (hazards ratio 
0.65, 96% CI 0.48–0.87; P = 0.004).50,65
More recently, the data of the I-PRESERVE trial have been 
published.66 This was a large, multicenter, placebo-controlled 
trial performed in a population of 4128 patients $60 years, 
with New York Heart Association Class II–IV heart failure 
and an ejection fraction $45%. Despite a reduction in blood 
pressure of 3.6/1.9 mmHg over four years of follow-up, 
irbesartan 300 mg once daily did not yield cardiovascular 
benefits over placebo on the primary composite outcome of 
all-cause mortality or hospitalization for a cardiovascular 
cause. These data tend to confirm the absence of benefits of 
renin-angiotensin-aldosterone system inhibition in patients 
with diastolic dysfunction.
Data from studies with angiotensin-converting enzyme 
inhibitors provided evidence that the renin-angiotensin-
aldosterone system is involved in atrial remodeling in atrial 
fibrillation. Some trials have evaluated the effect of irbesar-
tan in atrial fibrillation. A Spanish prospective trial showed 
that adding irbesartan to amiodarone was more effective in 
the maintenance of sinus rhythm than amiodarone alone in 
patients with persistent atrial fibrillation after cardiover-
sion to sinus rhythm.67 Patients treated with amiodarone-
irbesartan had a greater probability of remaining free of 
atrial fibrillation than patients treated with amiodarone alone 
over a median follow-up time of 254 days (79.5% versus 
55.9%, P = 0.007).
This finding has recently been reconfirmed in a random-
ized, controlled Chinese trial performed in patients with 
atrial fibrillation following rheumatic valve replacement and 
cardioversion. The combination of amiodarone and irbesartan 
demonstrated a higher rate of maintenance of sinus rhythm 
(69.8% versus 40.5%, P = 0.01) and better atrial fibrillation-
free survival (P = 0.006) than amiodarone alone during the 
one-year follow-up period.68
The ACTIVE-I study is part of a larger research program 
in atrial fibrillation, which 9016 patients enrolled in 41 coun-
tries were randomly assigned to receive irbesartan or placebo 
for a mean of 4.1 years.69 The study was completed in June 
2009. The difference in systolic blood pressure between the 
groups was approximately 3 mmHg. According to the study 
results, irbesartan was not associated with a reduction in the 
first coprimary endpoint of major vascular events, the com-
posite of cardiovascular death, heart attack, or stroke (5.4% 
per year in each group, P = 0.846). There was a slight but 
nonsignificant reduction in the second coprimary endpoint 
of major vascular events plus hospitalization for heart failure 
(7.3% in the irbesartan group versus 7.7% in the placebo 
group, P = 0.122) due to a 14% reduction in the risk for 
heart failure hospitalization in the irbesartan group versus 
the placebo group (2.7% versus 3.2%, P = 0.018). A post hoc 
analysis revealed a 13% reduction in the composite endpoint 
of stroke, non-central nervous system embolism, and tran-
sient ischemic attack in patients taking irbesartan versus 
placebo (2.9% versus 3.4%, P = 0.02).
Safety and tolerability
Poor adherence with therapy has been recognized as a causal 
factor of failure of blood pressure control.70 Persistence with 
a drug, defined as the time a patient remains on the prescribed 
medication, can be regarded as a good general indicator of the 
satisfaction of both patients and physicians with the efficacy 
and tolerability of the treatment. It is therefore not surprising 
that the persistence rate varies between drug classes. A British 
comparative study and a large Canadian cohort study showed 
angiotensin-converting enzyme inhibitors as the best and 
diuretics as the poorest persistence builders.70,71 Data regarding 
persistence with angiotensin receptor blockers, not yet included 
in the previous studies, are now emerging. Two population-
based trials including angiotensin receptor blockers revealed 
that patients have a better persistence with angiotensin receptor 
blockers than with all other antihypertensive drug classes up 
to three years.72,73 In a European cohort study of 2416 newly 
diagnosed hypertensive patients treated with monotherapy by 
general practitioners, irbesartan scored highest, with a persis-
tence rate at one year of 60.8%, compared with other angio-
tensin receptor blockers and other drug classes (Figure 1).74 
This improved persistence has been attributed in part to the 
efficacy of the compounds and mainly to the placebo-like side 
effect profile, verified for all clinically relevant dosages of 
irbesartan.23,24,37,75,76 In a pooled analysis of nine 4–12-week, 
placebo-controlled studies involving 2606 mild-to-moderate 
hypertensive patients, the overall incidence of adverse events 
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was similar in the irbesartan group (,900 mg once daily) and 
placebo-treated group (21% versus 20%, respectively), without 
clinical relevant differences in type of adverse events.75 Adverse 
events reported in $1% of irbesartan recipients and with a 
numerically higher incidence than with placebo, included diar-
rhea, dyspepsia/heartburn, and fatigue. None of these adverse 
events occurred at an incidence $5%. The tolerability profile 
of irbesartan is, in many aspects, comparable with that of other 
angiotensin receptor blockers.
The results of a post-marketing survey in Switzerland 
including 4769 hypertensive patients treated with irbesartan 
further emphasized the value of the good tolerability profile 
in enhancing treatment adherence.77 Of the 4639 patients 
with complete follow-up data, 82.5% were persistent with 
irbesartan for more than four months. The tolerability profile 
emerged as the most important predictive factor of long-term 
persistence with therapy. The favorable safety profile was 
also confirmed in long-term treatment. In two-year exten-
sion studies, irbesartan as monotherapy or as combination 
therapy with hydrochlorothiazide was associated with low 
discontinuation rates for adverse events (5.3%–9.1%) and 
low incidences of serious adverse events (5.3%–8.6%).78,79 
In previously reported comparison studies with other anti-
hypertensive major classes, the overall incidence of adverse 
events with irbesartan was similar to that of the comparator 
agent, including atenolol,28 enalapril,20–22,37 amlodipine,26 
doxazosin,38 aliskiren,36 and other angiotensin receptor 
blockers. The incidence of cough was significantly lower 
with irbesartan than with the angiotensin-converting enzyme 
inhibitor, enalapril (overall range 0%–10% versus 8%–21%, 
respectively).20–22,27 However, the incidence of cough was 
comparable with other angiotensin receptor blockers.
The good tolerability profile is conserved when irbesartan 
is administered in combination with hydrochlorothiazide, 
with an overall incidence rate of adverse events comparable 
with that of placebo. Adverse events, transient and mild, are 
similar to those found in irbesartan and/or hydrochlorothiazide 
monotherapy.32–34 Safety and tolerability of fixed-dose irbesar-
tan-hydrochlorothiazide for rapid control of severe hypertension 
has recently been confirmed in a randomized, controlled trial.80 
Despite more rapid and aggressive blood pressure-lowering, 
initial fixed-dose irbesartan- hydrochlorothiazide demonstrated 
a comparable adverse event profile to irbesartan monotherapy 
in patients with severe hypertension.
When considering hypertensive patients with type 2 
diabetes and nephropathy, the adverse event experiences 
were generally similar to those reported by the hypertensive 
population. However, in the population with overt nephropa-
thy in the IDNT trial, the incidence rates of dizziness, ortho-
static dizziness, orthostatic hypotension, and hyperkalemia 
($6.0 mmol/L) were significantly higher with irbesartan 
300 mg once daily than with placebo.50 The occurrence of 
hyperkalemia led to significantly higher discontinuation 
rates in the irbesartan treated-group (1.9%) than in the pla-
cebo (0.5%) or amlodipine group (0.4%, P = 0.01 for both 
between-group comparisons). Of note, hyperkalemia is a 
relative contraindication to the prescription of blockers of 
the renin-angiotensin system, and the addition of an angio-
tensin receptor blocker, on top of an angiotensin-converting 
enzyme inhibitor or a direct renin inhibitor, may favor the 
development of life-threatening hyperkalemia, particularly 
in patients with reduced renal function.
Recent research has focused on the impact of irbesartan 
on quality of life and exercise performance in cardiology 
patients. In a randomized, controlled trial focused on cardiac 
insufficiency symptoms, irbesartan added to angiotensin-
converting enzyme inhibitors produced significant improve-
ment in physical capacity (six-minute hall-walk distance, 
P , 0.01), exercise time (P = 0.01), New York Heart Associa-
tion class (P , 0.005), and quality of life score (P , 0.005) 
compared with placebo.81
Based on the results of IDNT, a number of modeled 
(Markov modeling) pharmacoeconomic analyses were 
 published.50 Treatment with irbesartan in hypertensive patients 
with type 2 diabetes and nephropathy resulted in improved 
life expectancy and appeared to be cost-saving compared 
with amlodipine or control therapy over a prospective period 
of 10 years and/or 25 years for the US, Canada, and some 
 European countries (Belgium, France, Italy, Spain, UK).82–87 
The early initiation of irbesartan (at the microalbuminuric 
stage) improved life expectancy and saved costs compared 
with later initiation (in the presence of overt nephropathy).88
100
90
80
70
60
50
40
30
20
10
0
34.4
Diuretics ACE
inhibitors
CCBs Losartan Beta
blockers
AIIRAs Irbesartan
42.0 43.6 44.7
49.7 51.3
60.8
P
at
ie
n
ts
 p
er
si
st
en
t 
w
it
h
 in
it
al
 a
g
en
t 
as
 
m
o
n
o
th
er
ap
y 
(%
)
*
Figure 1 Persistence at one year by antihypertensives.74
Copyright © 2002, Nature Publishing Group. Reproduced with permission from 
Hasford et al. http://www.nature.com/jhh/index.html
Notes: *P = 0.001 versus all other antihypertensive classes and versus losartan; 
P = 0.009 versus all other angiotensin II receptor antagonists. 
Abbreviations: ACe, angiotensin-converting enzyme; CCBs, calcium channel block-
ers; AIIRAs, angiotensin II receptor antagonists.
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Conclusion
Used as monotherapy or in association with  hydrochlorothiazide, 
irbesartan is an effective antihypertensive drug in a variety 
of mild-to-moderate hypertensive populations, including 
patients with diabetes, obesity, renal insufficiency, and cardio-
vascular disease. In comparative trials, irbesartan is at least as 
effective and sometimes superior to comparator agents of the 
major antihypertensive classes. There is some evidence that 
irbesartan provides protective cardiovascular effects beyond 
its antihypertensive action. This is particularly true for its 
beneficial effects on slowing the progression of early-stage 
and late-stage renal disease in hypertensive patients with type 
2 diabetes and on promoting regression of left ventricular 
mass in patients with hypertension and left ventricular hyper-
trophy. Recent research has further highlighted the positive 
role of irbesartan in preventing recurrence of arrhythmia 
in patients with persistent atrial fibrillation, when added to 
classical antiarrhythmic therapy. Finally, some data suggest 
an additional benefit in cardiac disease, through a reduction 
in the risk of heart failure episodes, as observed with other 
angiotensin receptor blockers.
In addition to its therapeutic efficacy, irbesartan can 
claim, like other angiotensin receptor blockers, an extremely 
favorable, placebo-like side effect profile, as has been shown 
in numerous real-life trials, even in the long term. It is there-
fore not surprising that irbesartan scores well for patient 
acceptation and adherence rates.
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